Drugs in R & D

, Volume 4, Issue 3, pp 149–158 | Cite as

Hydroxyethyl Starch (HES) [130/0.4], a New HES Specification

Pharmacokinetics and Safety after Multiple Infusions of 10% Solution in Healthy Volunteers
  • Josef Waitzinger
  • Frank Bepperling
  • Günther Pabst
  • Jens Opitz
Original Research Article


Objective: To investigate the pharmacokinetics and safety of a daily infusion of 500mL of hydroxyethyl starch (HES) [130/0.4] 10% solution on 10 consecutive days.

Study design and participants: An open, one-way, multiple-dose study was performed in 12 healthy male volunteers. Daily infusions over 30 minutes of 500mL of HES (130/0.4) 10% solution were performed on 10 consecutive days. Plasma and urine HES concentrations were determined repeatedly during the study until 72 hours after the last infusion.

Results: Maximum plasma HES concentrations, assessed with geometric means of 7.7 and 7.4 mg/mL, respectively, as well as the time courses of the plasma concentrations were similar on days 1 and 10 of treatment. Plasma HES concentrations 24 hours after the last infusion were 0.48 mg/mL (mean). Total plasma clearance was calculated as 23.7 and 21.8 mL/min on days 1 and 10, respectively. Urinary recoveries of 69% on day 1 and of 70% on day 10 were in good agreement.

Conclusion: The results clearly demonstrated that there is no relevant accumulation in plasma after repetitive infusion of the medium-molecular weight HES (130/0.4) solution, which exhibits a high renal excretion rate over 10 days. Local as well as systemic tolerability of 10 repeated doses was good.



The study was sponsored by Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany. We thank F. Cech (R&D Fresenius Kabi) for analysis of the HES concentrations in plasma and urine samples.


  1. 1.
    Treib J, Baron J-F, Grauer MT, et al. An international view of hydroxyethyl starch. Intensive Care Med 1999; 25: 258–68PubMedCrossRefGoogle Scholar
  2. 2.
    Gan TJ, Bennett-Guerrero E, Phillips-Bute B, et al. Hextend, a physiologically balanced plasma expander for large volume use in major surgery: a randomized phase III clinical trial. Anesth Analg 1999; 92: 1402–7Google Scholar
  3. 3.
    Fukusaki M, Nakamura T, Fukushima H, et al. Splanchnic perfusion during controlled hypotension with haemodilution under isoflurane anaesthesia in elderly patients. Eur J Anaesthesiol 1999; 16: 519–525PubMedGoogle Scholar
  4. 4.
    Vogt NH, Bothner U, Lerch G, et al. Large-dose administration of 6% hydroxyethyl starch 200/0.5 for total hip arthroplasty: plasma homeostasis, hemostasis, and renal function compared to use of 5% human albumin. Anesth Analg 1996; 83: 262–8PubMedGoogle Scholar
  5. 5.
    Waitzinger J, Bepperling F, Pabst G, et al. Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification [HES (130/0.4)] after single-dose infusion of 6% and 10% solutions in healthy volunteers. Clin Drug Invest 1998; 16: 151–60CrossRefGoogle Scholar
  6. 6.
    Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98)Google Scholar
  7. 7.
    Friedrich G, Ott E. Prospektive randomisierte Studie zum Wirkungsvergleich zwischen 10% HES 200/0.5 and 6% HES 200/0.5 bei Hörsturzpatienten. Laryngol Rhinol Otol 1991; 70: 670–4CrossRefGoogle Scholar
  8. 8.
    Mishler JM, Beez M. Die mathematische Beschreibung der intravasalen Ausscheidung von HAES nach der wiederholten Infusionen beim Menschen. Infusionsther Klin Ernahr 1979; 6 (2): 3–6Google Scholar
  9. 9.
    Asskali F, Föorster H. Zur Kumulation unterschiedlich substituierter Hydroxyethylstärke (HES) nach repetitiver Infusion bei gesunden Versuchsprobanden. Anasthesiol Intensivmed Notfallmed Schmerzther 1999; 34: 537–41PubMedCrossRefGoogle Scholar
  10. 10.
    Lehmann G, Asskali F, Förster H. Pharmacokinetics of hydrox-yethyl starch (70/0.5) following repeated infusions. Transfus Med Hemother 2003; 30: 72–7CrossRefGoogle Scholar
  11. 11.
    Koeltringer P, Pfeiffer P, Lind P, et al. Haemodilution mit mittelmolekularer Hydroxyaethylstaerke — 6% HES 200/0,6-0,66 - bei Patienten mit peripherer arterieller Verschluß-krankheit. Österr Krankenhauspharmazie 1989; 2: 7–12Google Scholar
  12. 12.
    Treib J, Haas A, Pindur G, et al. Influence of intravascular molecular weight of hydroxyethyl starch on platelets. Eur J Haematol 1996; 56: 168–72PubMedCrossRefGoogle Scholar
  13. 13.
    Kroemer H, Haass A, Müller K, et al. Haemodilution therapy in ischemic stroke: plasma concentrations and plasma viscosity during long-term infusion of Dextran 40 or Hydroxyethyl starch 200/0.5. Eur J Clin Pharmacol 1987; 31: 705–10PubMedCrossRefGoogle Scholar
  14. 14.
    Jung F, Koscielny J, Mrowietz C, et al. Elimination kinetics of different hydroxyethyl starches and effects on blood fluidity. Clin Hemorheol 1993; 14: 189–202Google Scholar
  15. 15.
    Metcalf W, Papadopoulos A, Tufaro R, et al. Clinical physiology study of hydroxyethyl starch. Surg Gynecol Obstet 1970; 131 (2): 255–67PubMedGoogle Scholar
  16. 16.
    Boldt J, Mueller M, Menges T, et al. Influence of different therapy regimens on regulators of the circulation in the critically ill. Br J Anesth 1996; 77: 480–7CrossRefGoogle Scholar
  17. 17.
    Aichner FT, Fazekas F, Brainin M, et al. Hypervolemic hemodilution in acute ischemic stroke: The Multicenter Austrian Hemodilution Stroke Trial (MAHST). Stroke 1998; 29: 743–9PubMedCrossRefGoogle Scholar
  18. 18.
    Trumble ER, Muizelaar JP, Myseros JS, et al. Coagulopathy with the use of hetastarch in the treatment of vasospasm. J Neurosurg 1995; 82: 44–7PubMedCrossRefGoogle Scholar
  19. 19.
    Strauss RG, Pennell BJ, Stump DC. A randomised, blinded trial comparing the hemostatic effects of pentastarch versus hetastarch. Transfusion 2002; 42: 27–36PubMedCrossRefGoogle Scholar
  20. 20.
    Huet RCG, Siemons AW, Baus D, et al. A novel hydroxyethyl starch (Voluven®) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anesth 2000; 47: 1207–15CrossRefGoogle Scholar
  21. 21.
    Langeron O, Doelberg M, Eng-Than A, et al. Voluven®, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg 2001; 92: 855–62PubMedCrossRefGoogle Scholar
  22. 22.
    Jungheinrich C, Scharpf R, Wargenau M, et al. The pharmaco kinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 ml) in mild-to-severe renal impairment. Anesth Analg 2002; 95: 544–51PubMedGoogle Scholar
  23. 23.
    Koehler H, Kirch W, Weihrauch TR, et al. Macroamylasaemia after treatment with hydroxyethyl starch. Eur J Clin Invest 1977; 7: 205–11CrossRefGoogle Scholar
  24. 24.
    Rosenzweig P, Miget N, Brohier S. Transaminase elevation on placebo during phase I trials: prevalence and significance. Br J Clin Pharmacol 1999; 48: 19–23PubMedCrossRefGoogle Scholar
  25. 25.
    Rudolf J. Hydroxyethyl starch for hypervolemic hemodilution in patients with acute ischemic stroke: a randomized, placebocontrolled phase II safety study. Cerebrovasc Dis 2002; 14: 33–41PubMedCrossRefGoogle Scholar
  26. 26.
    Neff TA, Doelberg M, Jungheinrich C, et al. Repetitive largedose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head trauma. Anesth Analg 2003; 96: 1453–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Josef Waitzinger
    • 1
  • Frank Bepperling
    • 2
  • Günther Pabst
    • 1
  • Jens Opitz
    • 2
  1. 1.AAI Deutschland GmbH & Co KGNeu-UlmGermany
  2. 2.FRESENIUS Kabi AG Deutschland GmbHBad HomburgGermany

Personalised recommendations